The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 39 of the 75 sources its claims cite were checked for support.
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Open accessPublished version of a preprint
Abstract
The efficacy of molecularly targeted therapies may be limited by co-occurring mutations within a tumor. Conversely, these alterations may confer collateral vulnerabilities that can be therapeutically leveraged. KRAS -mutant lung cancers are distinguished by recurrent loss of the tumor suppressor STK11/ LKB1. Whether LKB1 modulates cellular responses to therapeutic stress seems unknown. Here we show that in LKB1-deficient KRAS -mutant lung cancer cells, inhibition of KRAS or its downstream effector MEK leads to hyperactivation of JNK due to loss of NUAK-mediated PP1B phosphatase activity. JNK-mediated inhibitory phosphorylation of BCL-XL rewires apoptotic dependencies, rendering LKB1-deficient cells vulnerable to MCL-1 inhibition. These results uncover an unknown role for LKB1 in regulating stress signaling and mitochondrial apoptosis independent of its tumor suppressor activity mediated by AMPK and SIK. Additionally, our study reveals a therapy-induced vulnerability in LKB1-deficient KRAS- mutant lung cancers that could be exploited as a genotype-informed strategy to improve the efficacy of KRAS-targeted therapies.
Overview
CoChat Summary
TL;DR
In LKB1-deficient KRAS-mutant lung cancer cells, KRAS or MEK inhibition hyperactivates JNK because LKB1-NUAK signaling normally maintains PP1B phosphatase activity. JNK-mediated BCL-XL phosphorylation rewires apoptotic dependencies toward MCL-1, creating a genotype-informed vulnerability to combined KRAS/MEK + MCL-1 inhibition.
Key findings
- LKB1 loss sensitized KRAS-mutant NSCLC cells to MAPK + MCL-1 inhibition: LKB1-deficient lines showed greater ΔAUC for sotorasib + AMG 176 (*p* = 0.029) and trametinib + AMG 176 (*p* = 0.032), with robust apoptosis versus minimal apoptosis in LKB1 WT lines.
- Phosphoproteomics quantified 27,364 unique phosphosites and identified JNK1 as the only kinase signature enriched in trametinib-treated LKB1-deficient cells relative to WT but not in kinase-dead LKB1K87I cells.
- LKB1 suppresses JNK via NUAK1/2 and PP1B: NUAK1/2 knockdown restored drug-induced JNK phosphorylation and sensitivity, and PP1B knockdown increased pJNK and MAPK + MCL-1 inhibitor sensitivity.
- JNK phosphorylates BCL-XL at S62; BCL-XL S62A reduced sensitivity to sotorasib or trametinib + AMG 176 (*p* = 0.000001), while S62E increased sensitivity in LKB1-restored cells, consistent with reduced BIM sequestration by BCL-XL and increased MCL-1 dependence.
- In patient tumors and PDX models, STK11/LKB1-mutant tumors showed increased MCL-1-dependent priming after sotorasib or trametinib (*p* = 0.0002 for PDX), and sotorasib + AMG 176 improved tumor response and progression-free survival (p* = 0.00001; PFS p* = 0.0001).
Methods
- Preclinical study using KRAS-mutant NSCLC cell lines, isogenic LKB1 re-expression/knockout models, patient tumor explants, and PDX/xenograft mouse models.
- Main assays included CellTiter-Glo viability, annexin/PI apoptosis, western blot, co-immunoprecipitation, immunofluorescence/IHC, BH3 profiling, and mass spectrometry-based phosphoproteomics/proteomics.
- Analyses included ΔAUC for drug combinations, synergy testing by BIGL, phosphosite signature analysis, and statistical testing with t tests, one-way/two-way ANOVA, and mixed-effects models as specified in figure legends.
Limitations
- The paper states that the initial cell line cohort was limited and that heterogeneity was observed across cell lines; it also notes that future studies are needed to determine whether JNK phosphorylation of MCL-1 confers vulnerabilities in other therapeutic contexts.
- The paper states that no statistical method was used to predetermine sample size, no data were excluded, and investigators were not blinded to allocation during experiments and outcome assessment.
- Evident from the text: phosphoproteomic samples were analyzed as single biological replicates, and the clinical validation relies on a small patient sample and preclinical PDX/xenograft models rather than a prospective clinical trial.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
23 Valid · 1 Not valid · 8 Not checked · 116 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Preclinical studies have demonstrated that knockdown or suppression of KRAS or downstream signaling in KRAS-mutant cell lines often fails to induce apoptosis11–13.”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Introduction
What the sources say
- Not checked — no full text of the sourcecites [11] Singh, A. et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489–500 (2009). source
- Partly supportedcites [12] Corcoran, R. B. et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23, 121–128 (2013). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says MEK inhibition, which suppresses a downstream KRAS pathway, is largely cytostatic and caused less than 25% apoptosis in 90% of KRAS-mutant cell lines tested. This supports the claim about downstream signaling, but the passages do not establish that KRAS knockdown itself often fails to induce apoptosis. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [13] Hata, A. N. et al. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 74, 3146–3156 (2014). source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Co-IP experiments revealed increased BIM bound to MCL-1 and BCL-XL after trametinib treatment (Fig. S10A–C), consistent with prior studies16.”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > JNK phosphorylates BCL-XL to drive an MCL-1 dependent state
What the sources say
- Supportedcites [16] Nangia, V. et al. Exploiting MCL1 dependency with combination MEK + MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non-small cell lung cancer. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-18-0277 (2018). source
The Results section reports that trametinib increased BIM binding to MCL-1 in H2030 cells. It also reports BIM accumulation on both BCL-XL and MCL-1 in H1734 cells after trametinib treatment, supporting the citing sentence's reference to prior findings. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Phosphorylation of BCL-XL S62 induces a conformational change in which a dysregulated domain folds into the BCL-XL BH3 binding groove to prevent BIM binding58.”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > JNK phosphorylation alters BIM:BCL-XL interaction
What the sources say
- Partly supportedcites [58] Follis, A. V. et al. Regulation of apoptosis by an intrinsically disordered region of Bcl-xL. Nat. Chem. Biol. 14, 458–465 (2018). sourceExperimental — accuracy not yet measured
The Results sections ‘IDR phosphorylation enhances binding to the folded core’ and ‘IDR modification lowers Bcl-xL’s affinity for BH3 domains’ support a conformational mechanism that reduces BIM BH3 binding. They place the modified intrinsically disordered region at a site adjacent to the BH3 groove, where it hinders groove opening, rather than showing it folding into the groove; BIM binding is reduced, not prevented. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Discussion
What the sources say
- Partly supportedcites [1] Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014). sourceExperimental — accuracy not yet measured
The Recurrent alterations in key pathways section identifies a major mTOR pattern associated with STK11-inactivating mutations or low STK11 expression. The Molecular subtypes section likewise identifies an LKB1–AMPK-inactive group. These groups are described among lung adenocarcinomas generally, not specifically as major genomic subgroups of KRAS-mutant cancers. (LLM, conf=0.84)
- Supportedcites [19] Skoulidis, F. et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5, 860–877 (2015). source
The Results section reports that STK11/LKB1 mutations are enriched in the KL subgroup of KRAS-mutant lung adenocarcinoma. It also associates somatic mutations or bi-allelic deletions with subgroup allocation and reports enrichment of LKB1-inactivating events in KL tumors. Page numbers are not provided in our copy. (LLM, conf=0.93)
- Could not verifycites [62] Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596–609 (2017). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies STK11 as a tumor suppressor altered in some lung adenocarcinomas, while the Results (page unavailable) discuss KRAS-mutant tumors separately. Searches for STK11/LKB1 co-occurrence with KRAS and KRAS-mutant genomic subgroups found no passage establishing that STK11 inactivation defines a major subgroup. (LLM, conf=0.73)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we measured the level of several CRTC2/CREB target genes that are repressed by active LBK1-SIK signaling in tumors34, confirming decreased gene expression in isogenic LKB1-expressing xenograft tumors compared to the LKB1-null controls (Fig. S4B).”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > Modulation of LKB1 expression alters apoptotic response
What the sources say
- Supportedcites [34] Gritti, I. et al. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-24-0634 (2024). source
The Results section on CRTC2/CREB transcriptional reprogramming states that LKB1 activates SIKs, which restrain CRTC2/CREB signaling, and reports reduced CRTC2 target-gene expression when SIK signaling is restored. The isogenic LKB1 xenograft comparison is presented as the citing authors’ own result (Fig. S4B), not as a result attributed to this source. Page numbers are unavailable in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
71 more claims · 1 with their cited sources checked
Create a free account to see all 148 claims and to verify the 14 references still open.
- It may state two separate claims as one. 47
- Probably not a substantial claim. 34
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > Modulation of LKB1 expression alters apoptotic response
“E Subcutaneous xenograft tumors were established from H2030 EV and H2030 LKB1 cell lines, and mice were treated with vehicle, sotorasib (30 mg/kg daily), trametinib (3 mg/kg daily), AMG 176 (50 mg/kg daily) or combination.”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Methods > Mouse xenograft studies
“Sotorasib was dissolved in 2% HPMC/0.1% Tween 80 (pH 7) and administered by oral gavage daily at 100 mg/kg, 6 days per week.”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > LKB1-deficient patient and PDX tumors are MCL-1 dependent
“To extend these findings, we performed BH3 profiling on KRAS-mutant (G12C and other) NSCLC patient-derived xenograft (PDX) models with or without co-occurring STK11 loss after short-term treatment with trametinib. Similar to the patient tumors and in vitro cell line models, LKB1-deficient tumors exhibited increased MCL-1-dependent priming compared to WT tumors (Fig. 6D, S12B).”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > LKB1-deficient patient and PDX tumors are MCL-1 dependent
“D Mice bearing KRASG12C-mutant NSCLC patient derived xenograft (PDX) tumors were treated with sotorasib (100 mg/kg) for 3 days and harvested for BH3 profiling.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Discussion
“Furthermore, we observed that knock-down of LKB1 suppressed drug-induced JNK activation to varying degrees in different cell lines, suggesting that additional context-specific pathways may cooperate to regulate JNK.”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > JNK activation is associated with MCL-1 dependence
“Re-expression of LKB1 suppressed JNK phosphorylation in H2030 cells, and conversely, deletion of LKB1 in H358 cells led to increased phospho-JNK after drug treatment (Fig. 3C, S6A).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > JNK activation is associated with MCL-1 dependence
“expression of a kinase-dead LKB1K781 (kd) mutant25 did not rescue LKB1-deficient cells from combined MEK + MCL-1 inhibition”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > JNK activation is associated with MCL-1 dependence
“but not enriched in H2030 EV versus kinase-dead LKB1K87I cells.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > Modulation of LKB1 expression alters apoptotic response
“H358: **p = 0.007. For Trametinib, H2030: **p = 0.003, H2122: *p = 0.026, H23: **p = 0.002, A549: *p = 0.007”
§ LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers > Results > Modulation of LKB1 expression alters apoptotic response
“For Sotorasib, H2030: **p = 0.002, H2122: *p = 0.012, MGH1112-1: *p = 0.014, MGH1114-1: *p = 0.037, H358: **p = 0.007.”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484 · cited 1×
“Protein identi fi cation from from MS2 spectra was performed using the SEQUEST algorithm searching across a human data base (uniprot 2014) 92 using a custom analytical pipeline 89 .”
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419 · cited 1×
“STK11 , which encodes the protein LKB1 (Liver Kinase B1), is inactivated in ~30% of KRAS -mutant lung cancers 18 .”
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925 · cited 2×
“The search strategy included a target-decoy database-based search to fi lter against a false-discovery rate (FDR) of 1% 91 .”
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“LKB1 is a master serine/threonine kinase that regulates multiple cellular process including growth 26,35 , cell metabolism 20,21 , and cell polarity 36 – 38 .”
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188 · cited 1×
“Upon exposure of H2030 EV or LKB1 cells to UV light, a well-established inducer of JNK signaling 43,44 , weobservedanincreaseinphospho-JNKinH2030EVcellsthatpeaked within 60min (Fig.”
Signal integration by JNK and p38 MAPK pathways in cancer development
Wagner, E. F., & Nebreda, Á. R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2694 · Cited by 2,586 · cited 1×
“As JNKs modulate cell proliferation, differentiation and survival in response a number of different environmental and cellular stressors 42 , we examined whether hyperactivation of JNK signaling in LKB1-de fi cient cells is speci fi c to MAPK inhibition or re fl ects a more general role for regulation…”
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Consistent with prior studies of KRAS G12C inhibitors 2,7,30,31 , we observed varying sensitivity to KRAS G12C inhibition, which in our limited cell line cohort was independent of the most common co-occurring mutations such as TP53 , STK11 /LKB1 and KEAP1 (Fig.”
Self-citationThe LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 2×
“For instance, LKB1 plays a central role in energy homeostasis by sensing increased intracellular AMP/ATP ratio and phosphorylating AMPK, whichin turn suppresses energy consumptionby inhibiting mTOR and stimulating autophagy 45 .”
Hibi, M., Lin, A., Smeal, T., Minden, A., & Karin, M. (1993) · Genes & Development · doi:10.1101/gad.7.11.2135 · Cited by 1,886 · cited 1×
“Upon exposure of H2030 EV or LKB1 cells to UV light, a well-established inducer of JNK signaling 43,44 , weobservedanincreaseinphospho-JNKinH2030EVcellsthatpeaked within 60min (Fig.”
Cited by
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu, S., Ma, J., Cai, C., Tan, J., Deng, X., Shen, H., Zeng, S., Chen, Y., & Han, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03444-1 · Cited by 14
Deciphering the critical roles of the AMPK/mTOR signaling pathway in cancer cell metabolism (Review)
Alasadi, A., Fadhil, N. M., & Chen, S. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.391 · Cited by 8
“In addition, lung adenocarcinoma presents a special model for acknowledging the dual roles of AMPK due to the high mutation rate pf LKB1, the main upstream signaling kinase that controls the activation of AMPK (185).”
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors
Takamori, S., Haratake, N., Bhattacharya, A., Ozawa, H., Shigeta, K., Onishi, M., Nonaka, K., Komiya, T., Komatsuda, H., Takenaka, T., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03934-2 · Cited by 1
“In extending these results with patient-derived cells, we found that M1C ADC treatment of MGH1138 cells is effective in suppressing clonogenic survival (Fig.”
Self-citationSmall-molecule activation of the tumor suppressor kinase LKB1 via the pseudokinase STRAD
Song, L., Mitchell, D. C., Liu, J., Leak, L. B., Turnham, R. E., Wang, L., Wang, Z., He, C., Ding, L., Adler, M., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.07.013 · Cited by 4
Parker, K., Ghorbanpoor, S., Malik, W., Highfield, L., Wang, J., Hensley, E., Kelley, G., Clark, S., Ranieri, M., Sahu, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.718135 · Cited by 1
“Patient-derived cell lines (MGH1062-1, MGH1088-1, MGH1112-1, MGH1114-1, MGH1138-1, and MGH1143-2) were established in our laboratory from core biopsy or pleural effusion samples as previously described 26,41 .”
Self-citation
Metadata
- Authors
- Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., Clark, S. E., Kelley, G., Hensley, E. M., Morris, R., Lazaro, R., Belmonte, B., Oh, A., Walcott, M., Nabel, C. S., Caenepeel, S., Saiki, A. Y., Rex, K., Lipford, J. R., Heist, R. S., Lin, J. J., Haas, W., Sarosiek, K., Hughes, P. E., & Hata, A. N.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Medical University of South Carolina (US)
- Amgen (United States) (US)
- Corresponding author
- Hata, Aaron N.
- ORCID
- Li, Chendi
- Syed, Mohammed Usman
- Shen, Yi
- Fraser, Cameron
- Inde, Zintis
- Qin, Xingping
- Kreuzer, Johannes
- Clark, Sarah E.
- Hensley, Emily M.
- Morris, Robert
- Lazaro, Raul
- Nabel, Christopher S.
- Caenepeel, Sean
- Saiki, Anne Y.
- Rex, Karen
- Heist, Rebecca S.
- Lin, Jessica J.
- Haas, Wilhelm
- Sarosiek, Kristopher
- Hughes, Paul E.
- Hata, Aaron N.
- Venue
- Nature Communications
- Published
- 2025-05-02
- Volume
- 16
- Issue
- 1
- Pages
- 4112-4112
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC12048556
- OpenAlex
- W4410029176
- Cited by
- 11
- References
- 93
- Citations by year
- 2026: 8 · 2025: 3
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- American Association for Cancer Research (SU2C-AACR-DT17-15)
- Conquer Cancer Foundation
- Amgen
- American Society of Clinical Oncology
- Entertainment Industry Foundation
- Massachusetts Institute of Technology
- National Institutes of Health
- Stand Up To Cancer (SU2CAACR- DT17-15)
- Ludwig Center at Harvard
- National Heart, Lung, and Blood Institute (T32HL007118)
- National Cancer Institute (F32CA250231, P50CA265826)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- LKB1, STK11, KRAS-mutant lung cancer, JNK signaling, stress signaling, apoptosis, Bcl-xL, Mcl-1, MEK inhibition, KRAS-targeted therapy, mitochondrial apoptosis
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Humans, Lung Neoplasms, Mutation, Phosphorylation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Apoptosis, Protein Serine-Threonine Kinases, MAP Kinase Signaling System, Cell Line, Tumor, bcl-X Protein, Mice, AMP-Activated Protein Kinases, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers. https://app.cochat.ai/papers/10.1038/s41467-025-58753-y
- The paper
- Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., Clark, S. E., Kelley, G., Hensley, E. M., Morris, R., Lazaro, R., Belmonte, B., Oh, A., Walcott, M., Nabel, C. S., . . . Hata, A. N. (2025). LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers. Nature Communications. https://doi.org/10.1038/s41467-025-58753-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.